Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 25Other hematologic neoplasm 18CNS 11Thoracic 6Breast 6Myeloid 3Dermatologic 2Sarcoma 1Plasma cell 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Dexamethasone 262Lenalidomide 157daratumumab 135Bortezomib 113pomalidomide 89Calcium Dobesilate 86Cyclophosphamide 84carfilzomib 76Specimen Handling 46isatuximab 44fludarabine 43Biopsy 43belantamab mafodotin 41Magnetic Resonance Spectroscopy 38dexamethasone acetate 34dexamethasone 21-phosphate 34auricularum 33Melphalan 32talquetamab 29ixazomib 27iberdomide 27fludarabine phosphate 24selinexor 22elotuzumab 21Whole-Body Irradiation 17X-Rays 15venetoclax 14Mycophenolic Acid 13tocilizumab 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Spinal Puncture × Plasma cell × 1 year × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡